Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO 140 SC Injection in HIV-1
NCT02257788Phase 2Withdrawn
- Sponsor
- Drexel University
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of leronlimab in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Drexel University. Primary endpoint: Maximum change in viral load at 59 days. Planned start Sep 2014; status: withdrawn.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02257788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257788.